Apogee Therapeutics Inc.

03/22/2026 | Press release | Distributed by Public on 03/22/2026 17:54

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic[...]

Webcast to be held Monday, March 23rd at 8:00 a.m. ET

SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details
Apogee Therapeutics' live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company's website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
[email protected]

Media Contact:
Dan Budwick
1AB Media
[email protected]


Apogee Therapeutics Inc. published this content on March 22, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 22, 2026 at 23:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]